TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Clinical Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities

Trial Profile

TCD With Transfusions Changing to Hydroxyurea (TWiTCH): A Phase III Randomized Clinical Trial to Compare Standard Therapy (Erythrocyte Transfusions) With Alternative Therapy (Hydroxyurea) for the Maintenance of Lowered TCD Velocities in Pediatric Subjects With Sickle Cell Anemia and Abnormal Pre-treatment TCD Velocities

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2017

At a glance

  • Drugs Hydroxycarbamide (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Acronyms TWiTCH
  • Most Recent Events

    • 06 Dec 2016 Results of iron burden in the different organs (n=120) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Dec 2016 Results analysing agreement between measurements of dLIC over a period of one year by MRI R2 (FerriScan) and R2* methods, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Dec 2016 Primary endpoint has been met. (TCD Mean Velocity at 24 months on the index side) as per rsults presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top